Patient Web Site | Site Map | Contact Us

Press materials

Please click here for the latest news about CRESTOR.

For news about AstraZeneca, including financial information and information about upcoming events, or to access media relations professionals of AstraZeneca, visit our News Room.

Important safety information about CRESTOR

¹

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are or may become pregnant, and in nursing mothers.

Please see full Prescribing Information for CRESTOR.

CRESTOR was licensed from SHIONOGI & CO. LTD, Osaka, Japan.